Prof. Mark Slevin
FIBMS, PhD2, FAHA, ESOF, FRCPath
Professor of Cell Pathology
He was Director of the Centre for Biomedicine (currently bench-marked in the top 10 universities for medicine and biochemistry in UOA3) from 2016-2018 and was Manchester Met lead on dementia research-linked with the greater Manchester dementia consortium. UOA3 university committee member and university committee for research and knowledge exchange.
Prof. Slevin has full Professorial titles at the Universities of Targu Mures (Romania) where he is now Scientific Director of CCAMF. He also has titles at and Griffith University, (Australia) and Weifang Medical School in China. He is also visiting Chair in Clinical Biomedicine at the ICCC-CSIC, St Pau Hospital Barcelona and Adjunct Professor at both Almajmaah and Ha’il Universities in Saudi Arabia.
Prof. Slevin is also a Fellow of the Royal College of Pathologists and has been since 2008. He is also a consultant for Smith and Nephew pharmaceuticals (2012-1017) and LIPOGEMS incorporated, Regenesol, Cambridge Medical Technology, Lipocell LTD and UK-MEDU LTD (2017-).
Prof. Slevin is Senior Associate editor of Brain Pathology (IF 7.5) and Nature’s Scientific Reports (IF 4.8) and Frontiers Immunology (IF 8.8) amongst others. He is a nominated Fellow of American Heart and Stroke Association and of the Institute of Biomedical Scientists in the UK.
His major research interests with current ongoing projects are: 1) Examining the involvement of monomeric C-reactive protein in the development of neuro-inflammation and dementia; as well as its role in schitzophrenia, sleep disorders and depression (with Manchester, UK, Max Planck, Germany and Barcelona University, Spain). 2. Identification of novel drug-releasing scaffolds for the treatment of acute ischaemic stroke (with Craiova, Romania). 3. The role of p17 protein and its variants from HIV, in B cell clonogenecity, PAR-receptor activation and thrombotic interaction in Alzheimer’s disease (with Brescia, Italy, Manchester, UK).